245 related articles for article (PubMed ID: 17041286)
21. A prototype approach toward antipsychotic medication adherence in schizophrenia.
Freudenreich O; Tranulis C
Harv Rev Psychiatry; 2009; 17(1):35-40. PubMed ID: 19205965
[TBL] [Abstract][Full Text] [Related]
22. Subjective assessments of the quality of life, well-being and self-efficacy in patients with schizophrenia.
Chino B; Nemoto T; Fujii C; Mizuno M
Psychiatry Clin Neurosci; 2009 Aug; 63(4):521-8. PubMed ID: 19531107
[TBL] [Abstract][Full Text] [Related]
23. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.
Holzinger A; Loffler W; Muller P; Priebe S; Angermeyer MC
J Nerv Ment Dis; 2002 Sep; 190(9):597-603. PubMed ID: 12357093
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
25. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
[TBL] [Abstract][Full Text] [Related]
26. Investigation of insight formation using narrative analyses of people with schizophrenia in remission.
Ko NY; Yeh ML; Hsu ST; Chung HH; Yen CF
J Nerv Ment Dis; 2006 Feb; 194(2):124-7. PubMed ID: 16477191
[TBL] [Abstract][Full Text] [Related]
27. Factors affecting quality of life in a multiracial sample of older persons with schizophrenia.
Bankole AO; Cohen CI; Vahia I; Diwan S; Kehn M; Ramirez PM
Am J Geriatr Psychiatry; 2007 Dec; 15(12):1015-23. PubMed ID: 18056820
[TBL] [Abstract][Full Text] [Related]
28. Predictors of subjective and objective quality of life in outpatients with schizophrenia.
Yamauchi K; Aki H; Tomotake M; Iga J; Numata S; Motoki I; Izaki Y; Tayoshi S; Kinouchi S; Sumitani S; Tayoshi S; Takikawa Y; Kaneda Y; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T
Psychiatry Clin Neurosci; 2008 Aug; 62(4):404-11. PubMed ID: 18778437
[TBL] [Abstract][Full Text] [Related]
29. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
Rettenbacher MA; Burns T; Kemmler G; Fleischhacker WW
Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893
[TBL] [Abstract][Full Text] [Related]
30. Correlates of subjective quality of life in people with schizophrenia: findings from the EuroSC study.
Marwaha S; Johnson S; Bebbington P; Angermeyer MC; Brugha T; Azorin JM; Kilian R; Kornfeld A; Toumi M;
J Nerv Ment Dis; 2008 Feb; 196(2):87-94. PubMed ID: 18277215
[TBL] [Abstract][Full Text] [Related]
31. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
Naber D; Lambert M; Karow A
Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
[TBL] [Abstract][Full Text] [Related]
32. [Adherence to antipsychotic medication in schizophrenia patients].
Baloush-Kleinman V; Poyurovsky M; Koren D; Schneidman M; Weizman A; Shnitt D
Harefuah; 2002 Dec; 141(12):1042-9, 1090. PubMed ID: 12534202
[TBL] [Abstract][Full Text] [Related]
33. Mediating role of illness representation among social support, therapeutic alliance, experience of medication side effects, and medication adherence in persons with schizophrenia.
Rungruangsiripan M; Sitthimongkol Y; Maneesriwongul W; Talley S; Vorapongsathorn T
Arch Psychiatr Nurs; 2011 Aug; 25(4):269-83. PubMed ID: 21784285
[TBL] [Abstract][Full Text] [Related]
34. Effect of thought disorders on quality of life in patients with schizophrenia.
Ulas H; Akdede BB; Ozbay D; Alptekin K
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):332-5. PubMed ID: 17854967
[TBL] [Abstract][Full Text] [Related]
35. Pharmacophilia and pharmacophobia: determinants of patients' attitudes towards antipsychotic medication.
Sibitz I; Katschnig H; Goessler R; Unger A; Amering M
Pharmacopsychiatry; 2005 May; 38(3):107-12. PubMed ID: 15902579
[TBL] [Abstract][Full Text] [Related]
36. Collaboration in outpatient antipsychotic drug treatment: analysis of potentially influencing factors.
Klingberg S; Schneider S; Wittorf A; Buchkremer G; Wiedemann G
Psychiatry Res; 2008 Nov; 161(2):225-34. PubMed ID: 18922582
[TBL] [Abstract][Full Text] [Related]
37. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
Linden M; Scheel T; Eich FX
J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up.
de Haan L; van Amelsvoort T; Dingemans P; Linszen D
Pharmacopsychiatry; 2007 Nov; 40(6):264-8. PubMed ID: 18030650
[TBL] [Abstract][Full Text] [Related]
39. Medication adherence and quality of life among Nigerian outpatients with schizophrenia.
Adelufosi AO; Adebowale TO; Abayomi O; Mosanya JT
Gen Hosp Psychiatry; 2012; 34(1):72-9. PubMed ID: 22036736
[TBL] [Abstract][Full Text] [Related]
40. Strategies for dosing and switching antipsychotics for optimal clinical management.
Buckley PF; Correll CU
J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
